SCHEMBL6016566

SCHEMBL6016566

CC(Nc1ncnc2[nH]cnc12)c1ccc(O)c(O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
HSD17B10 Q99714 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
EGFR P00533 13/20 0.40
AURKA O14965 1/20 0.38
RPS6KB1 P23443 1/20 0.38
RECQL P46063 4/20 0.37
TDP1 Q9NUW8 4/20 0.37
KDM4E B2RXH2 4/20 0.37
MAPT P10636 3/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
NFKB1 P19838 1/20 0.37
THPO P40225 1/20 0.37
HIF1A Q16665 1/20 0.37
POLB P06746 1/20 0.37
APEX1 P27695 1/20 0.37
MTOR P42345 1/20 0.37
BLM P54132 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6016571 0.81 SMN1; SMN2 (0.67) LMNAHSD17B10SMN1; SMN2HIF1A
SCHEMBL14713436 0.80 LMNA (0.64) LMNAHSD17B10SMN1; SMN2EGFRAURKA
SCHEMBL5019518 0.80 LMNA (0.64) LMNAHSD17B10SMN1; SMN2EGFRAURKA
SCHEMBL2623141 0.80 LMNA (0.64) LMNAHSD17B10SMN1; SMN2EGFRAURKA
SCHEMBL6016516 0.79 EGFR (0.45) EGFRAURKARPS6KB1
SCHEMBL9203092 0.74 SMN1; SMN2 (0.36) LMNAHSD17B10SMN1; SMN2HIF1A
SCHEMBL6016359 0.74 CCNB2 (0.54)
SCHEMBL5019511 0.74 MAP4K4 (0.40) LMNAHSD17B10SMN1; SMN2TDP1KDM4E
SCHEMBL18917315 0.73 AURKA (0.43) EGFRAURKARPS6KB1
SCHEMBL2803759 0.73 CCNB2 (0.47) LMNAHSD17B10SMN1; SMN2EGFRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244668-B1 PURINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF UNIVERSITAIRE INSTELLING ANTWE (BE) 2006-04-05 EP claimed
US-20030187261-A1 Purine derivatives, process for their preparation and use thereof USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) 2003-10-02 US claimed
US-20030187261-A1 Purine derivatives, process for their preparation and use thereof USTAV EXPERIMANTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187261-A1 Purine derivatives, process for their preparation and use thereof DCK, DTYMK, CCNK LMNA 1866/4885HSD17B10 4662/4885SMN1; SMN2 2887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.